Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: new aspects after the fall of the pyramid and the rise of new therapeutics.
Aletaha
Daniel
D
Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Vienna General Hospital, Waehringer Guertel 18-20, A-1090 Vienna, Austria. daniel.aletaha@akh-wien.ac.at
Smolen
Josef S
JS
D000970:Antineoplastic Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis* / Q000188:drug therapy*; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005544:Forecasting; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008134:Long-Term Care; D008297:Male; D011379:Prognosis; D016059:Range of Motion, Articular / Q000187:drug effects / Q000502:physiology; D020127:Recovery of Function; D015203:Reproducibility of Results; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents